| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 1,234 | 1,961 | 1,728 | 1,573 | 1,501 | 1,539 | 1,449 | 1,463 | 1,485 | 1,453 | 1,467 | 1,508 | 1,708 | 1,861 | 1,868 | 1,951 | 1,839 | 1,996 | 2,002 | 1,977 | 1,927 | 2,018 | 1,991 | 1,980 | 1,954 | 2,160 | 2,154 | 2,142 | 2,160 | 2,322 | 2,277 | 2,449 | 2,461 | 2,582 | 2,654 | 2,746 | 2,726 | 2,839 | 2,815 | 2,795 |
| Expenses | 992 | 1,035 | 976 | 1,118 | 1,016 | 1,114 | 1,099 | 1,127 | 1,139 | 1,077 | 1,088 | 1,104 | 1,344 | 1,395 | 1,421 | 1,490 | 1,740 | 1,481 | 1,464 | 1,426 | 1,398 | 1,395 | 1,382 | 1,388 | 1,355 | 1,457 | 1,477 | 1,570 | 2,055 | 1,635 | 1,612 | 1,767 | 1,764 | 1,800 | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 |
| EBITDA | 242 | 926 | 752 | 455 | 485 | 425 | 350 | 336 | 346 | 376 | 379 | 404 | 364 | 466 | 447 | 461 | 99 | 515 | 538 | 551 | 529 | 623 | 609 | 592 | 599 | 703 | 677 | 572 | 105 | 687 | 665 | 682 | 697 | 782 | 819 | 883 | 864 | 884 | 865 | 900 |
| Operating Profit % | 13 % | 45 % | 41 % | 26 % | 31 % | 26 % | 22 % | 20 % | 18 % | 20 % | 22 % | 23 % | 19 % | 24 % | 24 % | 24 % | 5 % | 25 % | 26 % | 26 % | 27 % | 31 % | 30 % | 30 % | 29 % | 31 % | 30 % | 25 % | 2 % | 29 % | 29 % | 28 % | 28 % | 29 % | 30 % | 31 % | 31 % | 31 % | 31 % | 31 % |
| Depreciation | 60 | 57 | 59 | 59 | 63 | 68 | 69 | 73 | 97 | 80 | 84 | 94 | 151 | 150 | 152 | 156 | 160 | 160 | 163 | 163 | 168 | 161 | 165 | 167 | 165 | 165 | 168 | 167 | 162 | 155 | 163 | 193 | 196 | 191 | 201 | 213 | 203 | 197 | 198 | 199 |
| Interest | 47 | 55 | 48 | 43 | 38 | 49 | 51 | 48 | 58 | 56 | 51 | 80 | 121 | 122 | 126 | 133 | 123 | 122 | 116 | 111 | 102 | 102 | 92 | 91 | 73 | 68 | 71 | 62 | 57 | 55 | 69 | 102 | 107 | 103 | 91 | 80 | 80 | 75 | 64 | 57 |
| Profit Before Tax | 155 | 875 | 681 | 377 | 410 | 346 | 253 | 245 | 244 | 266 | 272 | 259 | 134 | 232 | 205 | 275 | -150 | 279 | 296 | 319 | 293 | 402 | 384 | 357 | 383 | 484 | 472 | 357 | -87 | 532 | 463 | 419 | 433 | 531 | 559 | 631 | 631 | 656 | 661 | 691 |
| Tax | 25 | 225 | 172 | 87 | 126 | 54 | 46 | 16 | 38 | 78 | 68 | 201 | -94 | 69 | 26 | 29 | 2 | 63 | 52 | 68 | -21 | 81 | 74 | 60 | 59 | 154 | 156 | 108 | 31 | 178 | 151 | 127 | 146 | 153 | 173 | 188 | 182 | 199 | 208 | 188 |
| Net Profit | 130 | 650 | 509 | 290 | 284 | 292 | 207 | 229 | 206 | 188 | 204 | 58 | 228 | 163 | 179 | 246 | -152 | 216 | 244 | 251 | 314 | 321 | 310 | 297 | 324 | 330 | 316 | 249 | -118 | 354 | 312 | 292 | 287 | 378 | 386 | 443 | 449 | 457 | 453 | 503 |
| EPS in ₹ | 7.70 | 38.40 | 30.01 | 17.19 | 16.82 | 17.28 | 12.25 | 13.47 | 12.17 | 11.08 | 12.07 | 3.37 | 13.55 | 9.66 | 10.57 | 14.50 | -8.95 | 12.74 | 14.48 | 14.77 | 18.56 | 18.98 | 18.32 | 17.52 | 19.16 | 19.53 | 18.63 | 14.75 | -6.97 | 20.90 | 9.22 | 8.63 | 8.48 | 11.18 | 11.39 | 13.10 | 13.27 | 13.51 | 13.37 | 14.88 |
Torrent Pharmaceuticals
3,245.05
-26.40
(-0.81%)
Market Cap
1,10,720.70 Cr
EPS
48.94
PE Ratio
58.75
Dividend Yield
0.87 %
Industry
Healthcare52 Week High
3,590.70
52 Week Low
2,505.30
PB Ratio
14.58
Debt to Equity
0.72
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from25 analysts
Company News
View All News
Torrent Pharmaceuticals Issues Commercial Papers Worth 3 Billion Rupees7 hours ago
Torrent Pharmaceuticals has announced the issuance of commercial papers amounting to 3 billion Indian rupees. Commercial papers are short-term, unsecured debt instruments typically used by corporations for financing short-term liabilities.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,764.75 | 4,28,233.30 | 35.92 | 49,887.20 | 12.06 | 9,648 | 13.77 | 61.58 | |
| 5,840.65 | 1,56,910.50 | 74.97 | 8,184.00 | 0.89 | 1,600 | 64.53 | 55.23 | |
| 1,511.20 | 1,23,084.40 | 24.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 60.28 | |
| 3,245.05 | 1,10,720.70 | 58.75 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.68 | |
| 1,177.90 | 1,00,988.70 | 18.34 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.86 | |
| 2,398.05 | 97,867.10 | 48.47 | 10,615.60 | 19.57 | 1,942 | -16.38 | 56.07 | |
| 2,068.75 | 96,711.60 | 32.93 | 20,141.50 | 19.94 | 1,936 | 38.82 | 54.50 | |
| 907.35 | 92,945.80 | 20.14 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.54 | |
| 1,194.95 | 70,253.80 | 19.68 | 29,559.20 | 17.55 | 3,169 | -10.04 | 61.05 | |
| 31,101.85 | 66,026.50 | 49.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 61.04 |
Growth Rate
Revenue Growth
11.59 %
Net Income Growth
33.02 %
Cash Flow Change
37.92 %
ROE
20.26 %
ROCE
23.16 %
EBITDA Margin (Avg.)
6.33 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 7,904 | 9,058 | 9,702 | 14,243 | 14,121 | 14,010 | 14,075 | 13,100 | 15,012 | 15,061 |
| Fixed Assets | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,122 | 8,138 |
| Current Assets | 4,051 | 4,688 | 4,880 | 5,262 | 5,038 | 4,979 | 5,522 | 5,165 | 5,314 | 5,612 |
| Capital Work in Progress | 678 | 1,042 | 520 | 647 | 617 | 712 | 889 | 630 | 765 | 361 |
| Investments | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 |
| Other Assets | 4,095 | 4,378 | 4,691 | 5,249 | 5,403 | 5,763 | 5,940 | 5,821 | 5,926 | 6,389 |
| Total Liabilities | 7,904 | 9,058 | 9,702 | 14,243 | 14,121 | 14,010 | 14,075 | 13,100 | 15,012 | 15,061 |
| Current Liabilities | 2,824 | 3,286 | 2,738 | 5,202 | 5,165 | 5,454 | 4,892 | 4,415 | 5,447 | 5,425 |
| Non Current Liabilities | 2,589 | 2,278 | 2,613 | 4,418 | 4,231 | 3,732 | 3,346 | 2,732 | 3,367 | 2,779 |
| Total Equity | 2,491 | 3,495 | 4,351 | 4,623 | 4,724 | 4,823 | 5,837 | 5,953 | 6,198 | 6,856 |
| Reserve & Surplus | 2,406 | 3,410 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 |
| Share Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -90 | 438 | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 |
| Investing Activities | -2,113 | -870 | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 |
| Operating Activities | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 |
| Financing Activities | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Jul 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 68.31 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.14 % | 14.22 % | 14.46 % | 16.17 % |
| DIIs | 6.53 % | 6.71 % | 6.76 % | 6.78 % | 7.52 % | 7.82 % | 7.76 % | 8.89 % | 8.87 % | 9.00 % | 8.31 % | 7.16 % | 6.44 % | 7.26 % | 7.27 % | 7.08 % | 8.35 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.89 % | 7.72 % | 7.58 % | 7.29 % | 7.25 % | 7.10 % | 7.13 % | 4.59 % | 4.73 % | 4.47 % | 4.38 % | 4.25 % | 4.15 % | 4.09 % | 3.98 % | 4.34 % | 4.61 % |
| Others | 14.33 % | 14.33 % | 14.42 % | 14.68 % | 13.98 % | 13.83 % | 13.86 % | 15.27 % | 15.16 % | 15.28 % | 16.07 % | 17.34 % | 18.16 % | 3.27 % | 3.28 % | 2.87 % | 2.56 % |
| No of Share Holders | 0 | 72,616 | 64,525 | 64,309 | 67,205 | 63,229 | 62,933 | 64,557 | 67,866 | 63,831 | 61,572 | 69,612 | 69,117 | 71,154 | 74,765 | 79,848 | 85,035 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 14 | 14 | 17 | 32 | 35 | 48 | 22 | 28 | 0.00 |
| Dividend Yield (%) | 0.00 | 2.24 | 1.44 | 1.72 | 2.51 | 2.51 | 3.12 | 0.85 | 0.86 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Announcement under Regulation 30 (LODR)-Issue of Securities
Announcement under Regulation 30 (LODR)-Credit Rating
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Investor Presentation
Announcement under Regulation 30 (LODR)-Date of payment of Dividend
Announcement under Regulation 30 (LODR)-Dividend Updates
Corporate Action-Board approves Dividend
Board Meeting Outcome for Outcome Of Board Meeting Dated 24-Jan-25.
Results Q3 FY 2024-25.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Corporate Action-Board to consider Dividend
Board Meeting Intimation for To Consider And Approve The Audited Financial Results On Standalone Basis And Unaudited Financial Results And Interim Dividend
Closure of Trading Window
Partial Redemption Of Non-Convertible Debentures
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement Under Reg 30 Of LODR
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Investor Presentation
Board Meeting Outcome for Outcome Of Board Meeting Dated 25-10-2024
Results Q2 FY 2024-25
Announcement under Regulation 30 (LODR)-Credit Rating
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Issue of Securities
Announcement Under Regulation 30 Of LODR.
Technical Indicators
RSI(14)
Neutral 61.68
ATR(14)
Volatile 87.53
STOCH(9,6)
Overbought 89.09
STOCH RSI(14)
Overbought 94.59
MACD(12,26)
Bullish 31.26
ADX(14)
Weak Trend 22.61
UO(9)
Bearish 65.73
ROC(12)
Uptrend But Slowing Down 6.08
WillR(14)
Overbought -14.01
About Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited is a leading Indian pharmaceutical company with a global presence. It specializes in cardiovascular, central nervous system, vitamins and nutrients, gastro-intestinal, and anti-diabetes therapies. The company operates through wholly-owned subsidiaries in over 40 countries, with major operations in the US, Germany, and Brazil. Torrent Pharmaceuticals has manufacturing facilities in multiple Indian states and an R&D center in Ahmedabad. Founded in 1959, the company has grown through acquisitions, expansions, and product launches. It has entered various therapeutic segments including dermatology, gynecology, and oncology. Torrent Pharmaceuticals is engaged in research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations both domestically and internationally.
Website
Chairperson NameSudhir Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
